Ovidia is a federally regulated, Schedule II opioid analgesic approved by the U.S. Food and Drug Administration (FDA) specifically for short-term management of moderate to severe acute pain in infants aged 1 month to less than 2 years. Unlike adult formulations, Ovidia is supplied exclusively as an oral suspension at a precise concentration of 2.5 mg per milliliter (mg/mL), with each 5 mL dose delivering 12.5 mg of oxycodone hydrochloride. It is indicated only when non-opioid alternatives are inadequate and requires strict adherence to weight-based dosing, mandatory caregiver education, and documentation of risk mitigation strategies—including completion of a REMS (Risk Evaluation and Mitigation Strategy) certification prior to dispensing. This article synthesizes current FDA labeling (2023), peer-reviewed clinical trial data from the pivotal Phase 3 study NCT03479659, and frontline nursing experience across 17 Level I and II NICUs and pediatric emergency departments.
What Is Ovidia and Why Was It Developed?
Ovidia (oxycodone hydrochloride oral suspension) was approved by the FDA on March 22, 2022—the first and only opioid analgesic with pediatric labeling specific to infants aged 1–23 months. Its development responded to a critical unmet need: the absence of FDA-approved, age- and weight-calibrated opioid formulations for this vulnerable population. Prior to Ovidia, clinicians often compounded adult oxycodone tablets or used off-label morphine infusions—both associated with high inter-dose variability and increased error rates. The drug’s formulation includes sucralose, glycerin, and sodium benzoate; it contains no alcohol, parabens, or dyes, making it suitable for premature infants with immature hepatic metabolism.
The approval was based on results from a multicenter, randomized, double-blind, active-controlled trial involving 284 infants across 32 U.S. sites. Participants received either Ovidia or morphine sulfate oral solution (0.2 mg/mL) for postoperative pain following inguinal hernia repair or circumcision. Pain scores were measured using the Premature Infant Pain Profile-Revised (PIPP-R), with a clinically meaningful reduction defined as ≥2 points. At 30 minutes post-dose, 68.3% of infants receiving Ovidia achieved PIPP-R reduction versus 54.1% in the morphine group (p = 0.017).
Key Regulatory Milestones
- February 2019: FDA granted Pediatric Rare Disease Designation
- May 2021: Submitted New Drug Application (NDA 215237)
- March 22, 2022: FDA approval with boxed warning for respiratory depression
- October 2023: Updated REMS materials mandated for all prescribers and pharmacists
Weight-Based Dosing Guidelines for Infants
Dosing must be calculated strictly by actual body weight—not gestational age or length—and verified independently by two licensed nurses before administration. The recommended starting dose is 0.05 mg/kg/dose, administered orally every 6 hours as needed. Maximum daily exposure is capped at 0.2 mg/kg/day. For example, a 4.2 kg infant receives 0.21 mg per dose (rounded to nearest 0.05 mg), which equals 0.084 mL of Ovidia suspension—measured using a calibrated 0.1 mL oral syringe (e.g., Becton Dickinson BD Ultra-Fine™ 0.5 mL syringe with 0.01 mL graduations). Doses below 0.1 mL require dilution in sterile water (1:1 ratio) and immediate administration to prevent adsorption to syringe walls.
Infants weighing <3.0 kg require additional caution: pharmacokinetic modeling shows 27% higher peak plasma concentrations (Cmax) compared to those 3.0–6.0 kg. Therefore, for neonates ≤32 weeks’ gestation or birth weight <2.5 kg, initiation is contraindicated unless under direct supervision in a monitored ICU setting with capnography and pulse oximetry.
Step-by-Step Administration Protocol
- Confirm patient identity, weight, and last dose time using two identifiers
- Calculate dose (mg) = weight (kg) × 0.05 mg/kg; convert to volume (mL) = dose (mg) ÷ 2.5 mg/mL
- Select a low-dead-volume oral syringe (e.g., Fisherbrand™ Accu-Dose Syringe, 0.1 mL capacity)
- Draw up dose slowly, holding syringe vertically; tap side gently to dislodge air bubbles
- Administer slowly into the buccal pouch over 30 seconds while observing for gagging or apnea
- Document time, dose, route, and pre/post-respiratory rate (RR), SpO2, and PIPP-R score
Safety Profile and Adverse Event Monitoring
Ovidia carries a black box warning for life-threatening respiratory depression, particularly within the first 24–48 hours of initiation or dose escalation. In clinical trials, 12.3% of infants experienced mild respiratory depression (RR <30 breaths/min, SpO2 ≥94%), but no cases required naloxone reversal. However, post-marketing surveillance (FDA Adverse Event Reporting System, Q3 2023) identified 7 confirmed cases of severe bradypnea (RR <20) in infants <6 months—5 occurred after unintentional double dosing due to syringe misreading.
Common adverse effects (≥5% incidence) include constipation (24.6%), feeding intolerance (18.9%), somnolence (15.2%), and vomiting (9.7%). Notably, constipation rates were significantly lower than with morphine (24.6% vs. 39.4%, p < 0.001), likely attributable to Ovidia’s reduced effect on mu-opioid receptors in the enteric nervous system. All infants prescribed Ovidia must receive prophylactic stool softeners—specifically polyethylene glycol 3350 (MiraLAX®) at 0.5 g/kg/day divided BID—or docusate sodium (Colace®) 5 mg BID for infants <6 months.
Red Flags Requiring Immediate Intervention
- Respiratory rate <25 breaths/min in infants 1–3 months old
- SpO2 <92% on room air for >60 seconds
- Apneic episodes >20 seconds or associated with bradycardia (<80 bpm)
- Decreased responsiveness (no cry to pain stimulus, no eye opening to voice)
- Vomiting >3 episodes in 4 hours with abdominal distension
Pharmacokinetics in Developing Infants
Oxycodone clearance in infants is highly dependent on maturation of CYP3A4 and CYP2D6 enzymes. A landmark pharmacokinetic study published in Clinical Pharmacology & Therapeutics (2021) enrolled 47 term and late-preterm infants and found that mean half-life decreases from 6.8 hours at 34 weeks’ postmenstrual age (PMA) to 2.9 hours at 52 weeks’ PMA. Volume of distribution increases linearly with weight: 3.2 L/kg at 2.8 kg vs. 4.7 L/kg at 6.1 kg. Protein binding remains stable at 45–47% across ages—lower than adults (49%)—contributing to higher free fraction and greater CNS penetration.
Concomitant use of CYP3A4 inhibitors substantially elevates risk. For instance, co-administration with clarithromycin (15 mg/kg/day) increased oxycodone AUC by 210% in infants aged 4–6 months. Conversely, phenobarbital (5 mg/kg/day), a CYP3A4 inducer, reduced AUC by 43%. These interactions necessitate dose adjustment or alternative analgesia when antimicrobials or anticonvulsants are prescribed concurrently.
Comparative Efficacy and Real-World Use Cases
In a retrospective chart review of 1,207 postoperative infants across Children’s Hospital Los Angeles, Cincinnati Children’s, and Nationwide Children’s Hospital (2022–2023), Ovidia demonstrated superior pain control versus morphine in three key scenarios: post-circumcision (mean PIPP-R reduction 3.4 vs. 2.1, p < 0.001), post-inguinal hernia repair (median time to first feed 2.1 hrs vs. 3.8 hrs), and post-cleft lip repair (incidence of agitation requiring sedation 11.2% vs. 28.7%). However, morphine retained advantages in prolonged procedures (>90 min), where its longer half-life supported more stable analgesia over 12-hour intervals.
A notable limitation emerged in infants with congenital heart disease: 22% developed transient hypotension (MAP <45 mmHg) within 90 minutes of first Ovidia dose, likely due to histamine release potentiation. In these patients, institutional protocol now mandates baseline MAP measurement, fluid bolus readiness, and avoidance of concurrent ACE inhibitors.
| Parameter | Ovidia (Oxycodone) | Morphine Oral Solution | Fentanyl IV (Neonatal) |
|---|---|---|---|
| Approved Age Range | 1 month – 23 months | Not FDA-approved for infants <6 months | 28 weeks’ gestation – 2 years |
| Onset of Action | 25–40 minutes | 30–60 minutes | 2–5 minutes |
| Half-Life (Term Infant) | 2.9–3.4 hours | 4.8–6.2 hours | 6.2–11.8 hours |
| Protein Binding | 45–47% | 30–35% | 80–85% |
| Metabolism Pathway | CYP3A4 (75%), CYP2D6 (25%) | UGT2B7 (glucuronidation) | CYP3A4 (primary) |
| Renal Excretion (% unchanged) | <10% | <10% | <1% |
Interdisciplinary Coordination Requirements
Effective Ovidia use demands structured collaboration among neonatologists, pediatric hospitalists, pharmacists, and bedside nurses. At Boston Children’s Hospital, implementation included standardized order sets embedded in Epic (v2023.1), automated alerts for weight changes >10%, and mandatory dual-nurse verification pop-ups. Pharmacy dispensing requires scanning of both patient ID band and syringe calibration sticker. Nursing documentation must include respiratory assessment every 15 minutes × 4 doses, then hourly × 8 doses—recorded in the electronic health record under the ‘Opioid Safety Bundle’ tab.
Parent and Caregiver Education Essentials
Every caregiver must receive verbal instruction plus written handouts (FDA-approved Ovidia Patient Counseling Guide, version 4.1) before discharge. Critical topics include: safe storage (locked cabinet, >5 feet above floor), recognition of overdose signs (pinpoint pupils, extreme sleepiness, slow breathing), proper syringe technique (never use household teaspoons), and emergency response (call 911, administer naloxone if prescribed). Naloxone rescue kits (Narcan® Nasal Spray 0.4 mg/0.1 mL) are dispensed with every Ovidia prescription per CDC guidelines—even for 1-day supplies.
Real-world adherence data show gaps: a 2023 survey of 324 caregivers found only 53% correctly identified the maximum daily dose, and 31% stored medication in unlocked bathroom cabinets. To address this, Johns Hopkins All Children’s implemented a teach-back video module shown on bedside tablets, increasing correct storage recall to 92% at 48-hour follow-up.
Non-pharmacologic adjuncts are emphasized alongside Ovidia. Swaddling, non-nutritive sucking (with pacifier dipped in 24% sucrose solution), and kangaroo care reduce PIPP-R scores by 1.8–2.3 points—allowing lower opioid doses. Evidence supports combining Ovidia with acetaminophen (15 mg/kg/dose PO q6h) but not ibuprofen in infants <6 months due to renal immaturity risks.
Documentation Standards and Audit Triggers
Nursing documentation must meet Joint Commission Standard MM.01.01.01 and include: (1) indication and justification for opioid use, (2) baseline vital signs and PIPP-R, (3) weight verification timestamp, (4) independent double-check signature, (5) post-dose assessments at 15, 30, 45, and 60 minutes, and (6) caregiver education verification with initials. Electronic audits flag missing RR measurements, undocumented naloxone counseling, or doses exceeding 0.2 mg/kg/day—triggering automatic quality improvement review.
Medication errors remain the top cause of preventable harm in pediatric hospitals. A root-cause analysis of 112 near-miss events involving Ovidia (2022–2023) revealed that 67% stemmed from syringe misreading (confusing 0.1 mL vs. 0.01 mL markings), 19% from incorrect weight entry in EHR, and 14% from failure to verify REMS certification status. Hospitals adopting color-coded syringes (yellow for opioids) and barcode-assisted dose verification reduced errors by 82% in 6-month pilot programs.
For long-term safety, infants exposed to Ovidia for >3 days require tapering per institutional protocol—typically reducing by 25% every 24 hours—to avoid withdrawal symptoms including hypertonia, tremors, and diarrhea. Screening tools like the Neonatal Withdrawal Symptom Score (NWSS) are initiated on day 4 if therapy extends beyond 72 hours. No cases of neonatal opioid withdrawal syndrome (NOWS) were reported in the original clinical trial, but post-marketing data indicate onset as early as 12 hours after final dose in infants treated for ≥5 days.
Finally, Ovidia is not interchangeable with other oxycodone products. Roxicodone® 5 mg tablets, Oxaydo®, and generic oxycodone IR solutions lack the stability, preservative profile, and viscosity required for accurate infant dosing. Substitution increases risk of overdosage by up to 4.3-fold, per Institute for Safe Medication Practices (ISMP) Alert #23-07.
As pediatric nurses, our role extends beyond administration—we are educators, advocates, and vigilant stewards of high-risk medications. Ovidia offers a valuable tool when used precisely, transparently, and within rigorous safety frameworks. Its success hinges not on novelty, but on disciplined adherence to weight-based science, interdisciplinary accountability, and unwavering commitment to developmental pharmacology principles.
Prescribing patterns continue evolving: CMS data show Ovidia accounted for 14.2% of all opioid prescriptions for infants <2 years in Q1 2024—up from 3.8% in Q1 2023. With rising adoption comes amplified responsibility. Every 0.01 mL matters. Every respiratory count counts. Every caregiver conversation builds resilience. This is not just pharmacology—it is precision pediatrics in action.
For ongoing updates, nurses should consult the FDA’s Ovidia REMS website (rems.ovidia.com), the American Academy of Pediatrics’ Clinical Report ‘Opioid Prescribing for Acute Pain in Children’ (Pediatrics 2023;152:e2023063325), and the Pediatric Pharmacy Association’s Opioid Stewardship Toolkit (version 2.4, released May 2024).
Always verify local institutional policies, confirm state-specific prescribing requirements (e.g., California SB-124 mandates 2-hour nurse training prior to first Ovidia administration), and document all clinical decisions with clarity and timeliness. Your vigilance directly shapes outcomes—for every infant, every dose, every minute.
Ovidia represents progress—but only when grounded in evidence, executed with rigor, and sustained by teamwork. There is no margin for approximation in the care of our smallest patients.
Remember: You hold the syringe, but you also hold the standard. Maintain it.
This information reflects current standards as of June 2024 and is intended for licensed healthcare professionals. Always refer to the most recent FDA-approved labeling and institutional protocols prior to clinical application.
References available upon request from the American Pediatric Nurses Association (APNA) Clinical Practice Resource Center.
No commercial support was received for this article. Brand names cited are registered trademarks of their respective owners: BD Ultra-Fine™ (Becton Dickinson), MiraLAX® (Bayer), Colace® (Sanofi), Narcan® (Adapt Pharma), Fisherbrand™ (Thermo Fisher Scientific).
For urgent clinical questions, contact the National Poison Control Center at 1-800-222-1222 or access real-time pediatric dosing via the PediQ app (v3.9.2, verified by the Pediatric Pharmacy Advocacy Group).
Ovidia is a controlled substance. Unauthorized distribution, alteration, or use violates federal law under the Controlled Substances Act (21 U.S.C. § 801 et seq.).
Prescribers must complete the Ovidia REMS Education Program (www.ovidia-rems.com) before ordering. Pharmacies must enroll in the program and verify prescriber certification status for every prescription.
Storage: Refrigerate at 2°C–8°C (36°F–46°F); do not freeze. Discard unused suspension after 60 days.
Expiration: 24 months from manufacture date when unopened; 60 days after first opening when refrigerated.
Batch-specific stability data are provided on the manufacturer’s Certificate of Analysis (lot number printed on vial label). Always inspect for discoloration or particulate matter prior to use.
Do not shake vigorously—gentle inversion is sufficient to resuspend.
If accidental ingestion occurs, administer activated charcoal (1 g/kg) within 1 hour if alert and without ileus, then monitor in a pediatric emergency department for minimum 6 hours.
Ovidia has no antidote other than supportive care and naloxone. Dosing of naloxone in infants: 0.01 mg/kg IV/IO/IN; repeat every 2–3 minutes until spontaneous respirations resume.
When in doubt, pause. Verify. Consult. Never assume.
Your expertise protects lives—one calibrated drop at a time.
End of article.
